NEW YORK – Meridian Bioscience said on Monday that it has received an additional $2.5 million from the National Institutes of Health's Rapid Acceleration of Diagnostics initiative to develop its Revogene respiratory diagnostic panel.
The new award expands the firm's original $5.5 million grant from the agency to support the research, development, and increased production of its Revogene molecular viral respiratory diagnostic panel. The additional funding will offset the cost of development and enable Meridian to enhance its manufacturing line so it can increase production to meet the expected demand for the panel, the company said in a statement.
The panel will simultaneously detect SARS-CoV-2, respiratory syncytial virus, and influenza A/B.
"As COVID-19 moves from a pandemic to an endemic public health concern, our customers are requesting highly accurate respiratory testing panels to help speed and differentiate diagnosis so patients can get the best treatment and on the road to wellness," Tony Serafini-Lamanna, Meridian's executive VP of diagnostics, said in a statement.